エトドラク
Etodolac
Indole acetic acid derivative
別名: EtoGesic · Lodine · AY-24236 · etodolacum · etodolic acid · Acudor · Articulan · Dualgan · Eccoxolac · Edolan · Elderin · Etonox · Etopan · Flancox · Hypen · Lodot · Lonine · Metazin · Sodolac · Ultradol · Zedolac
VetSheet 獣医チームが監修更新日 2026年4月5日エビデンスに基づく獣医学リファレンス
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
動物種別用量
🌎 NA — North America🌍 EU — Europe
犬
| 適応 | 用量 | 経路 | 頻度 | 期間 | 地域 |
|---|---|---|---|---|---|
| Treatment of pain and inflammation associated with osteoarthritis | 10-15 mg/kg | PO | once daily | — | 🌎 NA |
| Treatment of pain and inflammation associated with osteoarthritis | 10-15 mg/kg | SC | once | — | 🌎 NA |
- Treatment of pain and inflammation associated with osteoarthritis: Dogs less than 5 kg cannot be accurately dosed with EtoGesic tablets. Adjust dose to obtain satisfactory response, but do not exceed 15 mg/kg. For long-term therapy, reduce dose level to minimum effective dosage.
- Treatment of pain and inflammation associated with osteoarthritis: Administer as a dorsoscapular subcutaneous injection. If needed, daily doses of tablets may begin 24 hours after the last injectable treatment. Use alternate injection sites.
用量は獣医専門家向けの臨床参考資料です。必ず最新の医薬品情報および個別症例に基づいて確認してください。
概要
エトドラクは、主に犬の変形性関節症に伴う疼痛および炎症の管理に獣医療で使用される非ステロイド性抗炎症薬（NSAID）です。
- 経口錠剤および注射剤の形態で利用可能です。
- 犬において比較的長い半減期を持ち、便利な1日1回投与が可能です。
- 臨床上のポイント: 有効である一方で、一部の新しい獣医用NSAIDと比較して治療域が狭いため、胃腸毒性を避けるためには正確な用量設定が不可欠です。治療用量のわずか2.7倍で胃腸障害を引き起こす可能性があります。
作用機序
Etodolac exerts its analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting the cyclooxygenase (COX) enzymes.
- Arachidonic Acid → Prostaglandins: By blocking COX, etodolac prevents the conversion of arachidonic acid into pro-inflammatory prostaglandins.
- It is generally considered a COX-1 sparing drug rather than highly COX-2 selective in dogs. In horses, it does not exhibit much COX-2 selectivity.
- Additionally, etodolac inhibits macrophage chemotaxis, which further blunts the inflammatory cascade at the site of tissue injury.
安全性・警告
禁忌
- Known hypersensitivity to etodolac
- Dogs less than 12 months of age
- Breeding, pregnant, or lactating dogs (safe use not established)
- Cats (highly sensitive to toxicity)
有害事象
- Vomiting
- Regurgitation
- Diarrhea
- Lethargy
- Hypoproteinemia
- Urticaria
- Behavioral changes
- Inappetence
- Hepatotoxicity (rare)
- Nephrotoxicity (rare)
- Localized pain or tissue reactions at injection site
- Decreased total serum T4
- Keratoconjunctivitis sicca (KCS)
注意事項
Use with caution in dogs with preexisting or occult GI, hepatic, renal, cardiovascular, or hematologic abnormalities as NSAIDs may exacerbate these conditions.
Important: Patients may be more susceptible to renal injury from etodolac if they are dehydrated, on diuretics, or have preexisting renal, hepatic, or cardiovascular dysfunction.
Terminate therapy if inappetence, vomiting, fecal abnormalities, or anemia are observed.
医薬品相互作用
May reduce antihypertensive effects and increase the risk for renal injury.
May decrease etodolac plasma levels and increase likelihood of GI adverse effects (blood loss). Concomitant use is not recommended.
May increase cyclosporine blood levels and increase the risk for nephrotoxicity.
May increase serum levels of digoxin. Use with caution in severe cardiac failure.
May reduce the saluretic and diuretic effects of furosemide.
Serious toxicity has occurred with concomitant NSAID use.
Potential for increased risk of nephrotoxicity.
May increase the metabolism of etodolac in dogs.
May cause a significant increase in serum levels and half-life of etodolac.
May increase the risk for bleeding.
監視
- Baseline physical exam, CBC, Serum chemistry panel (liver and renal function), and Urinalysis
- Reassess liver enzymes at one week of therapy
- Tear production (Schirmer Tear Test) prior to and during therapy due to KCS risk
- Clinical efficacy (pain scoring)
- Signs of adverse reactions: inappetence, vomiting, melena, diarrhea, PU/PD, jaundice, lethargy
薬物動態
半減期
吸収
Rapidly and nearly completely absorbed after oral administration. Food may alter the rate, but not the extent, of absorption. Peak serum levels occur about 2 hours post dosing. Oral bioavailability in horses is about 77%.
分布
Highly bound to serum proteins. In horses, volume of distribution is 0.29 L/kg.
代謝
Glucuronide conjugates have been detected in the bile but not the urine.
消失
Primarily excreted via the bile into the feces. Rate of enterohepatic circulation may be affected by the presence of food in the gut.
過剰投与
Etodolac has a relatively narrow therapeutic window in dogs.
- 2.7X overdose (40 mg/kg/day): Can cause GI ulcers, weight loss, emesis, and local occult blood.
- 5.3X overdose (80 mg/kg/day): Highly lethal; caused death or moribund state secondary to severe GI ulceration in safety studies.
- Feline Toxicity: Cats are highly sensitive. Exposures have resulted in acute renal failure, anorexia, collapse, hyperkalemia, and hypersalivation.
Treatment: Decontamination with emetics and/or activated charcoal may be appropriate for acute ingestions. Use gastrointestinal protectants for expected GI effects. If renal effects are anticipated, aggressive fluid diuresis is warranted.
製品
製剤
- Oral tablets
- Subcutaneous injection
動物用医薬品
- Etodolac Scored Tablets: 150 mg & 300 mg (EtoGesic)
- Etodolac Injection 10% (100 mg/mL) in 50 mL vials (EtoGesic Injectable)
ヒト用医薬品
- Etodolac Tablets: 400 mg & 500 mg
- Etodolac Capsules: 200 mg & 300 mg
- Etodolac Extended-release tablets: 400 mg, 500 mg & 600 mg
規制ステータス
規制データなし: 🇺🇸 US · 🇪🇺 EU · 🇬🇧 UK · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
保管・安定性
Veterinary tablets should be stored at controlled room temperature (15-30°C). Injection should be stored at or below 77°F (25°C).
飼主向け情報
投与方法: 獣医師の処方通りに正確に投与してください。胃の不調を和らげるため、食事と一緒に与えることをお勧めします。
副作用に注意: 犬に以下の症状が見られた場合は、直ちに投薬を中止し、獣医師に連絡してください。
- 嘔吐または吐き戻し
- 下痢または黒色タール便（メレナ）
- 食欲不振または極度の無気力
- 多飲多尿
目の健康: まれに、この薬は「ドライアイ」（乾性角結膜炎）を引き起こすことがあります。過度のまばたき、充血、またはドロドロした目やにに注意してください。
警告: 猫や他のペットには絶対に与えないでください。強い毒性を示し、致命的になる可能性があります。すべての動物や子供の手の届かないところに保管してください。
VetSheet医薬品リファレンスは獣医専門家の臨床意思決定支援を目的としており、専門的判断または製造業者の最新医薬品情報の代替にはなりません。